H1 2025 Financial Results
Key figures and metrics H1 2025
“Our strong performance in the first half of 2025 reflects our continued focus on caring for patients through the solid execution of our Value Creation Plan, including capitalizing on the ongoing strength of our Biopharma Business Unit while moving forward on other key priorities.”
Increasing momentum drives strong H1 financial performance and positions Grifols to meet its full-year 2025 guidance
INVESTORS
Financial Results
Financial results published by the company.
Media Center
Downloadable resources for media professionals.